Abstract:SCN–VAN connectivity may be an antidepressant target associated with depressive state changes and a predictor of treatment response to serotonin reuptake inhibitors. The within‐network hypoconnectivity in SCN and DMN may reflect a trait‐like abnormality in MDD. Lack of placebo control is a limitation of this study. In this study, the effects of antidepressants on large‐scale brain networks and the neural basis of individual differences in response were explored. A total of 41 patients with major depressive disorder (MDD) and 42 matched healthy controls (HCs) were scanned by resting‐state functional magnetic resonance imaging separately at baseline and after a 12‐week follow‐up. The patients with MDD received escitalopram for 12 weeks. After treatment, patients were classified into those with MDD in remission [MDDr, endpoint 17‐item Hamilton Depression Rating Scale (HAMD) total score ≤7] and those in nonremission (MDDnr). The human Brainnetome Atlas was used to define large‐scale networks and compute within‐ and between‐network resting‐state functional connectivity (rsFC). Results showed the decreased subcortical network (SCN)–ventral attention network (VAN) connectivity at baseline increased in patients with MDD after 12‐week treatment, and it was comparable with that of HCs. This change was only observed in patients with MDDr. However, the decreased within‐network rsFC in SCN and default mode network (DMN) persisted in all patients with MDD, including those with MDDr and MDDnr, after treatment. The strength of SCN–VAN connectivity at baseline was significantly negatively correlated with the reduction rate of HAMD score in all patients with MDD. Thus, SCN–VAN connectivity may be an antidepressant target associated with depressive state changes and a predictor of treatment response to serotonin reuptake inhibitors. The within‐network rsFC in SCN and DMN may reflect a trait‐like abnormality in MDD. These findings provide further insights into the mechanism of antidepressants and their individual differences in response. The trial name is "Appropriate technology study of MDD diagnosis and treatment based on objective indicators and measurement" (URL: http://www.chictr.org.cn/showproj.aspx?proj=21377; registration number: ChiCTR‐OOC‐17012566).

Mapping the effect of escitalopram treatment on amplitude of low-frequency fluctuations in patients with depression: a resting-state fMRI study

Frequency-Specific Changes in the Fractional Amplitude of the Low-Frequency Fluctuations in the Default Mode Network in Medication-Free Patients with Bipolar II Depression: A Longitudinal Functional MRI Study

Differential Effects of Antidepressant Treatment on Long-Range and Short-Range Functional Connectivity Strength in Patients with Major Depressive Disorder

The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder.

Amplitude of Low-Frequency Oscillations in First-Episode, Treatment-Naive Patients with Major Depressive Disorder: a Resting-State Functional MRI Study.

Short-term Effects of Escitalopram on Regional Brain Function in First-Episode Drug-Naive Patients with Major Depressive Disorder Assessed by Resting-State Functional Magnetic Resonance Imaging

Effects of escitalopram therapy on effective connectivity among core brain networks in major depressive disorder

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder

Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for modulating the brain activity in mild to moderate major depressive disorder:an fMRI Study

Spatio-temporal dynamics of EEG features during sleep in major depressive disorder after treatment with escitalopram:A pilot study

Amplitude of Low Frequency Fluctuation in First-onset Major Depressive Disorder by Antidepressant Treatment Investigated with Resting-state Functional MRI

Spatio-temporal Dynamics of EEG Features During Sleep in Major Depressive Disorder after Treatment with Escitalopram: a Pilot Study

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Altered Fractional Amplitude of Low Frequency Fluctuation Associated with Cognitive Dysfunction in First-Episode Drug-Naïve Major Depressive Disorder Patients

Effect of Escitalopram on Cognitive Function in Depression: A Mismatch Negativity Potentials Study

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Amplitude of Low-Frequency Oscillations in Major Depression as Revealed by Resting State Functional Magnetic Resonance Imaging

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest

Alterations of the amplitude of low-frequency fluctuation induced by repetitive transcranial magnetic stimulation combined with antidepressants treatment for major depressive disorder

Effect of short-term escitalopram treatment on neural activation during emotional processing

Eight‐week antidepressant treatment reduces functional connectivity in first‐episode drug‐naïve patients with major depressive disorder